|Year : 2020 | Volume
| Issue : 1 | Page : 1-3
Coronavirus disease-2019: A brief overview
Syed Nahid Basheer1, Syed Wali Peeran2
1 Department of Restorative Dentistry, Faculty of Dentistry, Jazan University, Jizan, KSA
2 Dental Department, AFH, Jizan, KSA
|Date of Web Publication||28-May-2020|
Syed Nahid Basheer
Faculty of Dentistry, Jazan University, Jizan
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Basheer SN, Peeran SW. Coronavirus disease-2019: A brief overview. Dent Med Res 2020;8:1-3
Coronavirus disease (COVID-19) is caused by a newly identified single-stranded enveloped nonsegmented positive-sense β-coronavirus (CoV) RNA virus. This new virus has been called severe acute respiratory syndrome CoV 2 (SARS-CoV-2). The first human case was reported in Wuhan, Hubei province of China, in December 2019. Initially, it was referred to as “Wuhan pneumonia” of unknown cause, and the cases were linked to Wuhan city's South China Seafood Market.,,,,,
Moreover, around the same time, the World Health Organization (WHO) was informed about the new outbreak. By mid-January, the virus was first isolated using human airway epithelial cells and sequenced. Furthermore, around the same time, 17 million people were quarantined; by the end of the month, 1 billion people were quarantined. Around January 31, 2020, COVID-19 was declared a public health emergency in the United States. On March 11, 2020, the WHO classified the outbreak as a pandemic.,
The WHO estimates the mortality rate of COVID 19 to be 3.4%, a mortality rate far higher than seasonal flu., However, these estimates are evolving as this mortality rate depicts those who report with the disease. A majority of those affected may experience a mild illness course, recover at home without medical care, and may go unnoticed.,, The patients who are with comorbidities including hypertension, diabetes, moderate to severe asthma, cardiovascular disease, chronic respiratory disease, and cancer have a higher rate of mortality., The overall death rate from COVID-19 rises sharply in the elderly >65 years, while it declines in children aged ≤9 years.,, The higher mortality rate in patients with underlying diseases and the older adults may be attributed to an increased susceptibility to infection and a predilection to serious outcomes, which may be associated with acute respiratory distress syndrome and cytokine storm., However, it should be known that COVID-19 also affects the young, and severe cases are also encountered among young adults.,, Recently Center for disease control and prevention. (CDC) noted that nearly 40% of those hospitalized with CoV in the US are younger than 55 years and 20% are between 20 and 44 years.,, A trend also appears that the death rate among men is higher than among women. As new data set in and as our understanding of the disease improves, we will get to implement different methods and tools to prevent, test, and treat the COVID-19 patients.
The SARS-CoV-2 is assumed to have a maximum incubation period of up to 2 weeks, whereas the average time for the deterioration of symptoms from their onset to the intensive care unit admission is around 10 days. The most common clinical manifestations of COVID-19 patients include fever, cough, chest tightness, dyspnea, fatigue, and a small population of patients who appeared with gastrointestinal infection symptoms., Chest radiographs and computed tomography findings showed focal unilateral to diffuse ground-glass opacities within 1–3 weeks, similar to infection with SARS-CoV.,,,
The SARS-CoV-2 has been identified to originate from mammals, particularly from bats similar to all other alpha- and beta-coronaviruses. The SARS-CoV-2 spreads mainly from the respiratory tract with a body of evidence pointing toward sustained human-to-human transmission through respiratory droplets and contact routes.,, A number of laboratory studies estimate the survival of the virus in the air for 3 to 5 days, while it can remain viable up to 24 h on cardboard and 72 h on plastic and stainless steel.,
The suggested drugs for the treatment of COVID-19 can be categorized into antivirals, anti-inflammatory drugs, immunosuppressive therapies, antimalarial drugs, traditional Chinese drugs, and other supportive treatment measures. Chloroquine and some antivirals such as remdesivir have shown promising results in vitro.,,, However, as these drugs are under trails and no antiviral drug has proven to be efficient in the treatment of the disease till date, the suggested treatment remains nonspecific, which includes providing adequate oxygen, nutritional support, and maintaining fluids and electrolyte balances., In addition, no approved vaccines against SARS-CoV-2 exist. However, several trials of vaccines for protection against COVID-19 are underway. Hence, with over 2,203,927 confirmed cases of SARS-CoV-2 and 148,749 deaths, maintaining physical distancing, staying home, and regular washing of hands, especially after visiting public places, is strictly recommended.,,, Medical professionals are advised to avoid elective procedures and use personal protective equipment with Valved Fold-Flat and molded protection masks which are over 95% effective in anticipated COVID-19 cases. It is appropriate to move to telemedicine in these difficult times and to keep ourselves safe and be serving our patients in the comfort of their homes.,
Further, with a lot of misinformation existing on social media and on different spurious websites, we as health-care providers must be careful., Hence, we request our readers, in particular health-care workers, in general, to keep themselves updated and receive information from trusted national and international governmental sources. Some of the useful sites to get the latest information are the following:
| References|| |
Sahay M, Kute V, Prasad N. Corona, COVID and kidney transplantation. Indian J Transplant 2020;14:1. [Full text]
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al
. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – An update on the status. Mil Med Res 2020;7:11.
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23:130-7.
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020;20:124-7.
Weston S, Frieman MB. COVID-19: Knowns, unknowns, and questions. mSphere 2020;5:e00203-20.
Park WB, Kwon NJ, Choi SJ, Kang CK, Choe PG, Kim JY, et al
. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci 2020;35:e84.
Somily AM, BaHammam AS. Coronavirus disease-19 (severe acute respiratory syndrome-coronavirus-2) is not just simple influenza: What have we learned so far?. J Nat Sci Med 2020;3:79-82. [Full text]
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al
. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect Dis 2020;S1473-3099(20)30243-7. doi: 10.1016/S1473-3099(20)30243-7. Online ahead of print.
Mahase E. Covid-19: Death rate is 0.66% and increases with age, study estimates. BMJ 2020;369:m1327.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109(6):1088-1095. doi: 10.1111/apa.15270. Epub 2020 Apr 14.
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343-6.
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection [published online ahead of print, 2020 Mar 12]. Lancet Infect Dis 2020;S1473-3099(20)30195-X. doi:10.1016/S1473-3099(20)30195-X.
Kotfis K, Skonieczna-Żydecka K. COVID-19: Gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol Intensive Ther 2020;40157. doi: 10.5114/ait.2020.93867. Online ahead of print.
Habibzadeh P, Stoneman EK. The novel coronavirus: A bird's eye view. Int J Occup Environ Med 2020;11:65-71.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al
. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al
. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al
. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020;20:425-34.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health 2020;25:278-80.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al
. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564-7.
Callaway E, Cyranoski D. China coronavirus: Six questions scientists are asking. Nature 2020;577:605-7.
Rabby II. Current drugs with potential for treatment of COVID-19: A literature review. J Pharm Pharm Sci 2020;23:58-64.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al
. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
. Cell Res 2020;30:269-71.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al
. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.
Carvalho T. COVID-19 Research in Brief: 4 April to 10 April, 2020 [published online ahead of print, 2020 Apr 10]. Nat Med 2020;10.1038/d41591-020-00009-x. doi:10.1038/d41591-020-00009-x.
Walter-McCabe HA. Coronavirus pandemic calls for an immediate social work response. Soc Work Public Health 2020;35:69-72.
Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. J Clin Pathol 2020;73:239-42.
Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020;126:104345.
Portnoy J, Waller M, Elliott T. Telemedicine in the era of COVID-19. J Allergy Clin Immunol Pract 2020;8:1489-91. [doi: 10.1016/j.jaip. 2020.03.008].